Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.86 |
| ▸ | MEN1 | O00255 | 1/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.80 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | CCR1 | P32246 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8540316 | 0.99 | HRH3 (0.84) | HRH3MEN1KMT2ACYP1A2CCR1 | |
| SCHEMBL491793 | 0.93 | HRH3 (1.00) | HRH3MEN1KMT2ACCR1 | |
| SCHEMBL491772 | 0.92 | HRH3 (1.00) | HRH3MEN1KMT2ACCR1 | |
| SCHEMBL8545622 | 0.91 | HRH3 (0.98) | HRH3MEN1KMT2ACCR1 | |
| SCHEMBL491855 | 0.91 | HRH3 (1.00) | HRH3MEN1KMT2ACCR1 | |
| SCHEMBL5289503 | 0.91 | HRH3 (0.98) | HRH3MEN1KMT2ACCR1 | |
| SCHEMBL7430746 | 0.91 | HRH3 (1.00) | HRH3MEN1KMT2ACCR1 | |
| SCHEMBL492046 | 0.91 | HRH3 (1.00) | HRH3MEN1KMT2ACCR1 | |
| SCHEMBL2443304 | 0.91 | HRH3 (0.95) | HRH3MEN1KMT2A | |
| SCHEMBL491898 | 0.91 | HRH3 (1.00) | HRH3MEN1KMT2ACCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5596002-A | TREATMENT OF ANTIBIOTIC RESISTANT MICROORGANISMS | HOFFMANN-LA ROCHE INC. (US) | 1997-01-21 | — | — | US | claimed |
| EP-0656353-A1 | Aminochinoline derivates useful in the treatment of malaria | F. HOFFMANN-LA ROCHE AG (CH) | 1995-06-07 | — | — | EP | claimed |
| WO-2008021210-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | COMBINATORX, INCORPORATED (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | CHDI, INCORPORATED | 2008-02-21 | — | — | US | disclosed |
| EP-0656353-B1 | Aminochinoline derivates useful in the treatment of malaria | HOFFMANN LA ROCHE (CH) | 1998-06-03 | — | — | EP | disclosed |
| US-5596002-A | TREATMENT OF ANTIBIOTIC RESISTANT MICROORGANISMS | HOFFMANN-LA ROCHE INC. (US) | 1997-01-21 | — | — | US | disclosed |
| EP-0656353-A1 | Aminochinoline derivates useful in the treatment of malaria | F. HOFFMANN-LA ROCHE AG (CH) | 1995-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | HTT, SNCA, NLN | HRH3 1281/4885MEN1 3687/4885KMT2A 1354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.